M
Martin Broadstock
Researcher at Wolfson Centre for Age-Related Diseases
Publications - 19
Citations - 672
Martin Broadstock is an academic researcher from Wolfson Centre for Age-Related Diseases. The author has contributed to research in topics: Parkinson's disease & Neural stem cell. The author has an hindex of 7, co-authored 18 publications receiving 569 citations. Previous affiliations of Martin Broadstock include King's College London & Royal Holloway, University of London.
Papers
More filters
Journal ArticleDOI
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease
Madhav Thambisetty,Andrew Simmons,Latha Velayudhan,Abdul Hye,James Campbell,Yi Zhang,Lars-Olof Wahlund,Eric Westman,Anna Kinsey,Andreas Güntert,Petroula Proitsi,John Powell,Mirsada Causevic,Richard Killick,Katie Lunnon,Steven Lynham,Martin Broadstock,Fahd Choudhry,David R. Howlett,Robert J. Williams,Sally I. Sharp,Cathy Mitchelmore,Catherine Tunnard,Rufina Leung,Catherine Foy,Darragh O'Brien,Gerome Breen,Simon J. Furney,Malcolm Ward,Iwona Kłoszewska,Patrizia Mecocci,Hilkka Soininen,Magda Tsolaki,Bruno Vellas,Angela Hodges,Declan G. Murphy,Sue Parkins,Jill C. Richardson,Susan M. Resnick,Luigi Ferrucci,Dean F. Wong,Yun Zhou,Sebastian Muehlboeck,Alan C. Evans,Paul T. Francis,Christian Spenger,Simon Lovestone +46 more
TL;DR: These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
Journal ArticleDOI
A role for APP in Wnt signalling links synapse loss with β-amyloid production
Christina Elliott,Ana I. Rojo,Elena M. Ribe,Martin Broadstock,Weiming Xia,Peter J. Morin,Peter J. Morin,Mikhail Semenov,Mikhail Semenov,George S. Baillie,Antonio Cuadrado,Raya Al-Shawi,Clive Ballard,Paul Simons,Richard Killick +14 more
TL;DR: It is reported that pharmacological inhibition of the Aβ-Dkk1-Aβ positive feedback loop with the drug fasudil can restore the balance between Wnt pathways, prevent dendritic spine withdrawal in vitro, and reduce Aβ load in vivo in mice with advanced amyloid pathology.
Journal ArticleDOI
Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies
TL;DR: This review summarises the current understanding of the underlying biology of AD, PDD and DLB and outlines the most recent drug candidates in advanced clinical trials.
Journal ArticleDOI
Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.
Dag Aarsland,Dag Aarsland,Dag Aarsland,Clive Ballard,Arvid Rongve,Martin Broadstock,Per Svenningsson +6 more
TL;DR: Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also reduce risk of falling, and recent evidence suggests that memantine may also be effective, particularly for PDD, although evidence is more conflicting.
Journal ArticleDOI
Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease
Gayathri N. Sekhar,Alice L. Fleckney,Sevda Tomova Boyanova,Huzefa Rupawala,Rachel Lo,Hao Wang,Doaa B. Farag,Doaa B. Farag,Khondaker M. Rahman,Martin Broadstock,Martin Broadstock,Suzanne Reeves,Sarah A. Thomas +12 more
TL;DR: The research indicates that the increased sensitivity of individuals with Alzheimer’s to amisulpride is related to previously unreported changes in function and expression of SLC transporters at the BBB (in particular PMAT and MATE1).